摘要
目的 探讨聚乙二醇干扰素α-2a联合利巴韦林治疗不同年龄慢性丙型肝炎患者的临床效果.方法 回顾性分析2010年1月～2014年1月本院收治的慢性丙型肝炎患者83例,根据年龄的不同将其分为＜60岁组（n=43）和≥60岁组（n=40）.两组患者均给予聚乙二醇干扰素α-2a联合利巴韦林治疗,观察比较两组的治疗效果及不良反应发生情况.结果 治疗48周后,＜60岁组患者的快速病毒学应答（RVR）率（65.1％）、早期病毒学应答（EVR）率（72.1％）、治疗结束时病毒学应答（ETVR）率（69.8％）、持续病毒学应答（SVR）率（51.2％）均高于≥60岁组（分别为50.0％、57.5％、87.5％、40.0％）,差异有统计学意义（P＜0.05或P＜0.01）;两组复发率、无效率比较,差异无统计学意义（P＞0.05）.＜60岁组患者中性粒细胞、血小板、血红蛋白下降率明显低于≥60岁组,差异有统计学意义（P＜0.05或P＜0.01）;两组患者主要不良反应为恶心、呕吐、乏力、脱发不适症状,且＜60岁组恶心、呕吐、乏力的发生率低于≥60岁组,差异有统计学意义（P＜0.05）.结论 老年慢性丙型肝炎患者抗病毒疗效较差,药物不良反应发生率较高,治疗上仍存在一定的难度,针对老年患者制订安全有效的抗病毒治疗方案,对于降低肝硬化、肝癌的发生率至关重要.
Objective To explore the therapeutic effect and safety of pegylated interferon α-2a combined with ribavirin in the treatment of different age patients with chronic hepatitis C. Methods 83 cases of patients with chronic hepatitis C from January 2010 to January 2014 in our hospital were retrospectively analyzed,and were divided into 〈60 years group （n=43） and ≥ 60 years group （n=40）.They were given with the treatment of pegylated interferon α-2a combined with ribavirin.The therapeutic effect and complications of two groups were compared. Results After 48 weeks treatment, the rate of rapid virological response （RVR） （65.1%）,early virological response （EVR） （72.1%）,the end of tratment viro- logical response（ETVR） （69.8%）,sustained virological response（SVR） （51.2%） of 〈60 years group was higher than that （50.0%,57.5%,87.5%,40.0%） of the ≥60 years group respectively,the difference was significant （P〈0.05 or P〈0.01）; while the recurrence rate and no efficiency rate of two groups had no significant difference （P〉0.05）.The droop rate of the neutrophile granulocyte,PLT,Hb of 〈60 years group was lower than that of the I〉60 years group respectively,the difference was significant （P〈0.05 or P〈0.01）.The main adverse reactions was nausea,vomiting,fatigue,hair loss symp- toms,and the occurrence rate of nausea,vomiting,fatigue of 〈60 years group was lower than that of the ≥ 60 years group respectively,the difference was significant （P〈0.05）. Conclusion Patients with elderly chronic hepatitis C has poor treatment outcome and more adverse reactions,and still has difficult in treatment,so it is very important to formulate a safe and effective scheme on antiviral treatment that specific to elderly patients for reduceing the incidence of liver cirrhosis and liver cancer.
出处
《中国当代医药》
2014年第34期79-82,共4页
China Modern Medicine
